Skip to content

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Natalie Gukasyan, Roland R. Griffiths, David B. Yaden, Denis Antoine, Sandeep M. Nayak

Journal of Psychopharmacology June 8, 2023 DOI: 10.1177/02698811231179910 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective survey Peer reviewed
Sample size 2,153
Population Individuals with use of psilocybin mushrooms with an antidepressant or within 2 years of discontinuing an antidepressant
Intervention psilocybin mushrooms
Topics Psilocybin Serotonin
Keywords Antidepressant Fluoxetine Discontinuation Bupropion Serotonin reuptake inhibitor Pharmacology Sertraline
Citations 60
Key findings SSRI/SNRIs appear to weaken psilocybin drug effects relative to bupropion, and this dampening may last up to three months following antidepressant discontinuation.

Abstract

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.

Aims: To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both concurrently and after discontinuation of antidepressants.

Methods: Online retrospective survey of individuals with use of psilocybin mushrooms (1) with an antidepressant and/or (2) within 2 years of discontinuing an antidepressant. Participants who took mushrooms with an antidepressant and either took the same dose pre-antidepressant or took the same dose with other people not on antidepressant reported the strength of drug effects relative to their expectation. Participants who took mushrooms following discontinuation of an antidepressant also reported the presence of weakened effects.

Results: In reports ( n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41–0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44–0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2–0.39] (bupropion). Following SSRI/SNRI discontinuation ( n = 1,542 reports), the probability of reduced drug effects was not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3–6 months, probability = 0.3 [0.20–0.46], p = 0.001. A sensitivity analysis found that removing responses involving fluoxetine, which has an especially long half-life, did not significantly alter this result.

Conclusions: SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant. This dampening effect may last as long as 3 months following antidepressant discontinuation.

Comparable studies

Other cross-sectional and survey studies on psilocybin, most cited first.

Study Year Design Participants
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... 2016 Cross-sectional survey n = 1,993
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin 2016 Questionnaire development and validation
Psychedelics and Mental Health: A Population Study Adult population in the United States 2013 Cross-sectional survey n = 130,152
Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... 2019 Cross-sectional survey n = 343
Patterns of simultaneous polysubstance use in drug using university students Drug-using university students 2006 Cross-sectional survey n = 149

Citations in the library

Cited by 54

and 49 more in the library

Cites 17

and 12 more in the library

Explore topics